NFE2L2 and metabolic dysfunction-associated steatotic liver disease: In summary, this study demonstrates that XOR inhibition by febuxostat alleviates hepatic steatosis, metabolic dysregulation, and plasma oxidative stress in male MASLD rats, an effect accompanied by alterations in the JNK/NRF2/HO-1 signaling pathway.